Physician profile
Richard Pleva
NPI 1194700914
$4,119.58
in general payments reported to CMS, 2019-2025
24 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $290 · 2021: $689 · 2022: $779 · 2023: $883 · 2024: $785 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,089.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $883.29 | 2019-2025 | |
| Gilead Sciences, INC. | $475.02 | 2019-2025 | |
| Genzyme Corporation | $341.95 | 2022-2024 | |
| Braintree Laboratories, INC. | $321.05 | 2019-2025 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $244.98 | 2023-2025 | Dupixent |
| Celgene Corporation | $224.99 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $217.08 | 2019-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.96 | 2019-2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $167.22 | 2020-2025 | |
| Madrigal Pharmaceuticals | $162.43 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $160.78 | 2019-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $153.30 | 2021-2023 | Zeposia |
| Pfizer INC. | $151.60 | 2021-2023 | |
| Lucid Diagnostics INC. | $101.32 | 2022 | |
| Echosens North America, INC. | $70.48 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $53.09 | 2020-2021 | |
| Digestive Care, INC. | $48.15 | 2020-2025 | Pertzye |
| Intuitive Surgical, INC. | $34.60 | 2020 | |
| Janssen Biotech, INC. | $23.66 | 2024 | Stelara |
| Nestle Healthcare Nutrition INC. | $21.54 | 2021 | |
| Capsovision, INC. | $16.28 | 2024 | Capsocam Plus |
| Laborie Medical Technologies Corp. | $16.18 | 2024 | Solar Uroflow System |
| Shionogi INC | $13.50 | 2019 | |
| Conmed Corporation | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Pleva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.